This study explores CD151’s (a protein linked to cancer progression) role in non-small cell lung cancer (NSCLC) patients without EGFR mutations, who have limited treatment options. Analysing 157 adenocarcinoma biopsies and 199 cases from The Cancer Genome Atlas, research led by A/Prof John Tam Kit Chung & A/Prof Thai Tran found high CD151 expression linked to poorer survival outcomes. CD151 interacts with EGFR, affecting EGF-induced cell proliferation and the efficacy of the EGFR inhibitor, erlotinib. CD151’s influence on survival and treatment response suggests it could be a valuable prognostic marker and therapeutic target in EGFR-negative NSCLC.

Click here to read more